Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 6Urinary Bladder Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 2Carcinoma, Transitional Cell 2Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Head and Neck Neoplasms 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1HER2-low Breast Cancer 1Gastric Adenocarcinoma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Breast Cancer 1

Interventions

Letrozole 5Fulvestrant 5trastuzumab deruxtecan 3Injections 3toripalimab 2sacituzumab govitecan 2palbociclib 2elacestrant 2abemaciclib 2Anastrozole 2AZD9833 2ribociclib 1pyrotinib 1exemestane 1eribulin 1disitamab vedotin 1dalpiciclib 1Vinorelbine 1Selective Estrogen Receptor Modulators 1Ritonavir 1RAD1901 1Paclitaxel 1Lead 1Itraconazole 1Goserelin 1Gonadotropin-Releasing Hormone 1Everolimus 1Docetaxel 1Bevacizumab 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Cancer × disitamab vedotin × 1 year × Clear all
NCT05831878 2026-05-13

RC48-ADC in HER2-low Advanced Breast Cancer

RenJi Hospital

Phase NA Recruiting
36 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡